Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 1
2004 1
2006 2
2007 1
2008 1
2009 2
2010 3
2011 6
2012 1
2013 3
2014 2
2015 1
2016 2
2017 2
2018 4
2019 1
2020 1
2021 3
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Wachsmann TLA, Wouters AK, Remst DFG, Hagedoorn RS, Meeuwsen MH, van Diest E, Leusen J, Kuball J, Falkenburg JHF, Heemskerk MHM. Wachsmann TLA, et al. Among authors: hagedoorn rs. Oncoimmunology. 2022 Feb 1;11(1):2033528. doi: 10.1080/2162402X.2022.2033528. eCollection 2022. Oncoimmunology. 2022. PMID: 35127255 Free PMC article.
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: hagedoorn rs. Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023. Front Immunol. 2023. PMID: 37026005 Free PMC article.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de Ru AH, van Hees EP, Kremer M, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: hagedoorn rs. J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6. J Hematol Oncol. 2023. PMID: 36850001 Free PMC article.
Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells.
van der Wulp W, Gram AM, Bleijlevens B, Hagedoorn RS, Araman C, Kim RQ, Drijfhout JW, Parren PWHI, Hibbert RG, Hoeben RC, van Kasteren SI, Schuurman J, Ressing ME, Heemskerk MHM. van der Wulp W, et al. Among authors: hagedoorn rs. Front Immunol. 2023 May 16;14:1183914. doi: 10.3389/fimmu.2023.1183914. eCollection 2023. Front Immunol. 2023. PMID: 37261346 Free PMC article.
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19.
Roukens AHE, Pothast CR, König M, Huisman W, Dalebout T, Tak T, Azimi S, Kruize Y, Hagedoorn RS, Zlei M, Staal FJT, de Bie FJ, van Dongen JJM, Arbous SM, Zhang JLH, Verheij M, Prins C, van der Does AM, Hiemstra PS, de Vries JJC, Janse JJ, Roestenberg M, Myeni SK, Kikkert M, Yazdanbakhsh M, Heemskerk MHM, Smits HH, Jochems SP; in collaboration with BEAT-COVID group; in collaboration with COVID-19 LUMC group. Roukens AHE, et al. Among authors: hagedoorn rs. Nat Immunol. 2022 Jan;23(1):23-32. doi: 10.1038/s41590-021-01095-w. Epub 2021 Dec 22. Nat Immunol. 2022. PMID: 34937933
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.
van Amerongen RA, Morton LT, Chaudhari UG, Remst DFG, Hagedoorn RS, van den Berg CW, Freund C, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: hagedoorn rs. Mol Ther Methods Clin Dev. 2023 Jan 20;28:249-261. doi: 10.1016/j.omtm.2023.01.005. eCollection 2023 Mar 9. Mol Ther Methods Clin Dev. 2023. PMID: 36816758 Free PMC article.
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA, Hagedoorn RS, Remst DFG, Assendelft DC, van der Steen DM, Wouters AK, van de Meent M, Kester MGD, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: hagedoorn rs. J Immunother Cancer. 2022 Jun;10(6):e004409. doi: 10.1136/jitc-2021-004409. J Immunother Cancer. 2022. PMID: 35728869 Free PMC article.
Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells.
van der Wulp W, Remst DFG, Kester MGD, Hagedoorn RS, Parren PWHI, van Kasteren SI, Schuurman J, Hoeben RC, Ressing ME, Bleijlevens B, Heemskerk MHM. van der Wulp W, et al. Among authors: hagedoorn rs. Cancer Gene Ther. 2024 Jan;31(1):58-68. doi: 10.1038/s41417-023-00681-4. Epub 2023 Nov 9. Cancer Gene Ther. 2024. PMID: 37945970 Free PMC article.
49 results